Page 43 - MBCA_FULL REPORT_FINAL_FOR_WEB

Table 4: MBC Trials Conducted by the Translational Breast Cancer Research Consortium

Trial # Status Trial Description Trial Presentations
TM
TBCRC Closed to An Open Label, Randomized, Phase II Trial of Abraxane 2013 SABCS Poster (Poster # P1-04-01);
019 Accrual (Paclitaxel Albumin-Bound Particles for Injectable 2013 ASCO Poster (Abstract # 1052);
Suspension), with or without Tigatuzumab (a Humanized 2011 ASCO Trials in Progress Poster
Monoclonal Antibody Targeting Death Receptor 5) (CS- (Abstract # TPS128)
1008) in Patients with Metastatic, Triple Negative (ER, PR,
and HER-2 Negative) Breast Cancer
TBCRC Closed to A Phase II Study of the PARP Inhibitor, Iniparib (BSI-201), 2014 Breast Cancer Research and Treatment
018 Accrual in Combination with Chemotherapy to Treat Triple Manuscript (PMID: 25001612 );
Negative Breast Cancer Brain Metastasis 2013 ASCO Poster Discussion Session
(Abstract # 515);
2011 ASCO Trials in Progress Poster
(Abstract # TPS127)
TBCRC Closed to Investigation of Genetic Determinants of Capecitabine N/A
015 Accrual Toxicity
TBCRC Closed to A Prospective Analysis of Surgery in Patients Presenting 2013 SABCS Poster (Poster # P2-18-09);
013 Accrual with Stage IV Breast Cancer 2013 ASCO Oral Presentation (Abstract # 507)
TBCRC Closed to Bicalutamide for the Treatment of Androgen Receptor 2013 Clinical Cancer Research Manuascript
011 Accrual Positive (AR(+)), Estrogen Receptor Negative, (PMID: 23965901);
Progesterone Receptor Negative (ER(-)/PR(-)) 2012 SABCS Poster (Poster # P6-05-02);
Metastatic Breast Cancer Patients: A Phase II Feasibility 2012 ASCO Oral Presentation (Abstract # 1006);
Study 2011 ASCO Trials in Progress Poster
(Abstract # TPS122)
TBCRC Closed to Phase I/II Study of Dasatinib in Combination with N/A
010 Accrual Zoledronic Acid for the Treatment of Breast Cancer
Bone Metastasis
TBCRC Closed to A Phase II Study of Cisplatin or Carboplatin for Triple- 2014 ASCO Oral Presentation (Abstract #1020);
009 Accrual Negative Metastatic Breast Cancer and Evaluation of 2012 SABCS Poster Discussion Session
p63/p73 as a Biomarker of Response (Poster Discussion # PD-09-03);
2012 Cancer Research Manuscript (PMID: 23135909 );
2011 ASCO Poster Discussion Session
(Abstract # 1025)
TBCRC Closed to MPA Revisited: A Phase II Study of Anti-Metastatic, Anti- 2010 ASCO Poster (Abstract # 1074)
007 Accrual Angiogenic Therapy in Postmenopausal Patients with
Hormone Receptor Negative Breast Cancer.
TBCRC Active A Phase 2 Study of Lapatinib in Combination with 2014 ASCO Poster Highlights Session
003 Trastuzumab in Patients with HER2-Positive, Metastatic (Abstract # 536);
Breast Cancer 2011 SABCS Poster (Poster # P2-09-07);
2011 2-ASCO Poster Discussion Sessions
(Abstract # 527 & 528);
2010 ASCO Trials in Progress Poster
(Abstract # TPS132)
TBCRC Closed to Phase II Trial of Cetuximab Alone and in Combination 2014 Science Signaling Manuscript (PMID: 24667376 );
001 Accrual with Carboplatin in ER-Negative, PR-Negative, HER2- 2012 JCO Manuscript (PMID: 22665533);
nonoverexpressing Metastatic Breast Cancers 2009 SABCS Poster;
2008 Molecular Markers Poster (Abstract # 2);
2008 ASCO Oral Presentation (Abstract # 1009);
2007 SABCS Poster Discussion Session
(Poster # 307)
Abbreviations: ASCO American Society of Clinical Oncology, SABCS = San Antonio Breast Cancer Symposium